The surprising outperformance of a new drug against existing competitors, and other biotech updates

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Today, we see a gene therapy succeed in helping patients with a rare liver disease maintain their blood sugar. We see an Ionis drug do better than already-approved competitors in a rare swelling disease, and we see some conflict-of-interest issues from doctors on X.

Also, ASCO starts today! If you haven’t already, sign up for our flash ASCO newsletter here. STAT’s Matt Herper, Adam Feuerstein, Angus Chen, and Elaine Chen will be reporting from McCormick Place in Chicago.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe

Log In